about
Psychedelics and mental health: a population studyPsychedelics and the human receptoromeThe mechanistic classification of addictive drugsInvestigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humansAVPR1a and SLC6A4 gene polymorphisms are associated with creative dance performance.The induction of synaesthesia with chemical agents: a systematic reviewRestructuring consciousness -the psychedelic state in light of integrated information theoryThe entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsPersonality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal studyPrediction of psilocybin response in healthy volunteersVisual trails: do the doors of perception open periodically?Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical rolesMetabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsDifferential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in miceHead-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Human hallucinogen research: guidelines for safetyMystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterThe HIV antiretroviral drug efavirenz has LSD-like propertiesLorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditurePsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsThe serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogenMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptorsNeural correlates of the psychedelic state as determined by fMRI studies with psilocybinMystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of opennessThe behavioral pharmacology of hallucinogens'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylaminesAgonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivoArresting serotoninVisual hallucinations: differential diagnosis and treatmentHigh specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligandMechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortexLysergic acid diethylamide: a drug of 'use'?Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 yearsNeuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like StimulantsThe Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of CivilizationLegal highs: staying on top of the flood of novel psychoactive substancesPreclinical models of antipsychotic drug action.Predicting monoamine oxidase inhibitory activity through ligand-based modelsKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy
P2860
Q21089784-64645656-5533-4266-B4BC-DA2167AA5E4DQ21090031-DB6426D2-56B5-4446-9364-E53D3D90F8A5Q21090144-8B55D39D-6494-4C4D-B69B-17B657821505Q21091087-D77BFC9F-F883-4250-977B-4790232407D4Q21092500-5CE964EB-B443-452C-B3B6-5C9CE8938094Q21129149-E52B080D-B98C-4901-8095-CD042B64AF61Q21129375-5AB758A6-5D5F-4E88-8A96-BB2FA62AC255Q21129387-FB177E42-74F7-4D9C-AD2B-BAC203A235FCQ21134103-F4144013-DE67-4CE1-8E68-4C4082FEB7EBQ21134798-AC1EEE7C-98E3-4252-B893-074E441504F8Q21145773-36D0570D-3777-4F6C-9D44-476BA23C78D1Q22241778-A5223861-38C4-4DD0-8824-34436F1D84B4Q22251267-ED7CAC03-DC70-43A5-866F-8C6D426D3B6AQ24594834-2E1E9262-224F-4969-A54B-AD689C02857FQ24595389-62B26A29-C2B3-479B-88CD-36A3B5C5F435Q24600704-603A11AC-8EE1-484E-A917-37BA018DDE7EQ24606321-ACBE42E7-C519-4619-842A-3DF367DB34DBQ24608183-25362617-E9A6-4DAF-A352-71CBCF3BBBFFQ24611940-C8C85E33-8202-4E8F-952C-743C4B156218Q24613764-5E108C25-0A09-427B-BC0D-F8157D148244Q24620468-F105815C-D8CA-4CBC-ABE8-81B942157E16Q24620764-3395F490-9130-4630-936E-64D586011AE7Q24630429-62347BD1-0A15-4859-9F42-72BE105186FBQ24633222-C5090259-A441-4547-AD86-C44E8CE796E8Q24634013-CF629524-5749-4AB1-B5CB-6579E27ECEAEQ24645656-17D4A089-11B8-4AF4-AB88-AE0633E3C294Q24645935-404D630B-5F2C-4BF4-961B-CBF8592FB059Q24647416-8C7153B2-094C-424B-B149-5D4EFCC1A09EQ24647492-405D087D-253E-4A68-B918-C31A7E64E9CEQ24653561-E995CEDE-7065-44DC-B9C5-31D7E036AADCQ24657969-4B71D6CA-0683-4644-84FF-478B879EFA2CQ24676304-F5D84108-43CF-44A7-A2C8-973165928FEAQ26746133-643D394A-AEA9-4EA7-9E7B-730822E97A3AQ26746137-EC4693DE-A755-49A8-B36C-BDA00CA2A99DQ26752739-B975AB4C-2904-45BB-86FA-968705CF1212Q26765995-88A23FE6-6F29-4B17-B2D2-FB630EDE1C92Q26799231-31F78F7E-F858-45C4-9620-A8987CD5E61CQ26827502-2B50EE97-1D39-445A-B9F3-6FDC015C7B1AQ26851907-D1C4C40B-58ED-447C-9FB2-1741CE3DF008Q27024227-200B2992-DADF-4E53-B5EE-902C8A478728
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hallucinogens
@ast
Hallucinogens
@en
Hallucinogens
@en-gb
Hallucinogens
@nl
type
label
Hallucinogens
@ast
Hallucinogens
@en
Hallucinogens
@en-gb
Hallucinogens
@nl
prefLabel
Hallucinogens
@ast
Hallucinogens
@en
Hallucinogens
@en-gb
Hallucinogens
@nl
P3181
P683
P1476
Hallucinogens
@en
P2093
David E Nichols
P304
P3181
P356
10.1016/J.PHARMTHERA.2003.11.002
P407
P577
2004-02-01T00:00:00Z